Literature DB >> 15741787

Treatment with stimulants among youths in a large California health plan.

Laurel A Habel1, Catherine A Schaefer, Peter Levine, Aradhana K Bhat, Glen Elliott.   

Abstract

OBJECTIVE: The aim of this study was to examine the use of stimulants among youths in a large and diverse health plan in California from 1996-2000.
METHODS: Computerized pharmacy, outpatient visit, and membership files were used to conduct a population-based analysis of stimulant use among over 500,000 enrollees aged 2-18 years. Annual prevalence rates of stimulant use were estimated by calendar year, age, gender, and geographic area.
RESULTS: The annual percentage of continuously enrolled 2- through 18-year-olds receiving at least one prescription for a stimulant rose from 1.86% (95% confidence interval (CI) 1.82-1.90) in 1996 to 1.93% (95% CI, 1.90-1.96) in 2000. An increase was observed only among girls 8 years of age or older and among boys 12 years or older. Use of methylphenidate decreased, whereas use of extended-release amphetamine products increased. Stimulant use was lower and use of other psychotropic drugs was higher among children with visits for attention-deficit/hyperactivity disorder (ADHD) and a coexisting psychiatric disorder than among those seen for ADHD alone. Of the 11,698 children receiving at least one stimulant in 2000, 24% of these children received a single prescription. Approximately 55% of stimulant prescriptions were written by physicians in pediatrics and 45% by physicians in psychiatry.
CONCLUSIONS: The prevalence of treatment with stimulants was lower than what generally has been reported in other parts of the United States; it increased by approximately 4% between 1996 and 2000, and was frequently short term or intermittent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741787     DOI: 10.1089/cap.2005.15.62

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  9 in total

1.  A discrete choice conjoint experiment to evaluate parent preferences for treatment of young, medication naive children with ADHD.

Authors:  Daniel A Waschbusch; Charles E Cunningham; William E Pelham; Heather L Rimas; Andrew R Greiner; Elizabeth M Gnagy; James Waxmonsky; Gregory A Fabiano; Jessica A Robb; Lisa Burrows-Maclean; Mindy Scime; Martin T Hoffman
Journal:  J Clin Child Adolesc Psychol       Date:  2011

2.  Early intervention in pediatrics offices for emerging disruptive behavior in toddlers.

Authors:  Jannette McMenamy; R Christopher Sheldrick; Ellen C Perrin
Journal:  J Pediatr Health Care       Date:  2010-01-06       Impact factor: 1.812

3.  The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.

Authors:  Ingrid Schubert; Ingrid Köster; Gerd Lehmkuhl
Journal:  Dtsch Arztebl Int       Date:  2010-09-10       Impact factor: 5.594

4.  Development of an instrument to measure parents' preferences and goals for the treatment of attention deficit-hyperactivity disorder.

Authors:  Alexander G Fiks; Stephanie Mayne; Cayce C Hughes; Elena Debartolo; Carina Behrens; James P Guevara; Thomas Power
Journal:  Acad Pediatr       Date:  2012-06-28       Impact factor: 3.107

5.  Sex differences in effectiveness of extended-release stimulant medication among adolescents with attention-deficit/hyperactivity disorder.

Authors:  Amori Yee Mikami; Daniel J Cox; Margaret T Davis; H Kent Wilson; R Lawrence Merkel; Roger Burket
Journal:  J Clin Psychol Med Settings       Date:  2009-05-06

6.  Acute neuropharmacological effects of atomoxetine on inhibitory control in ADHD children: a fNIRS study.

Authors:  Masako Nagashima; Yukifumi Monden; Ippeita Dan; Haruka Dan; Daisuke Tsuzuki; Tsutomu Mizutani; Yasushi Kyutoku; Yuji Gunji; Daisuke Hirano; Takamichi Taniguchi; Hideo Shimoizumi; Mariko Y Momoi; Eiju Watanabe; Takanori Yamagata
Journal:  Neuroimage Clin       Date:  2014-09-10       Impact factor: 4.881

7.  Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies.

Authors:  Erik Parens; Josephine Johnston
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-01-19       Impact factor: 3.033

8.  Understanding the agreements and controversies surrounding childhood psychopharmacology.

Authors:  Erik Parens; Josephine Johnston
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-02-08       Impact factor: 3.033

9.  Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.

Authors:  Michael Schlander
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2007-11-15       Impact factor: 3.033

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.